Company Overview and News
The Snap Inc (NYSE:SNAP) boom/bust cycle I’ve talked about repeatedly this year remains in full swing. After an impressive surge off all-time lows, it’s time once again for SNAP stock to reverse course.
This week, music streaming platform Pandora Media Inc. (NYSE:P) made its way 10% higher after the company announced a new social media partnership with Snap Inc. (NYSE:SNAP). The deal will allow Snapchat users to share their favorite songs with friends on the app and has been praised as an important step forward for Pandora stock.
SPOT AAPL P SNAP
Sirius XM (SIRI) announced today via an SEC filing that the company has reached a settlement with SoundExchange regarding royalties. The dispute is now a decade old, and while $150 million seems like a steep price, it works out to just $10 million per year, a sum that the company can easily absorb. The Street seems to have liked the news in that Sirius XM's stock continues to set new 52-week highs.
LSXMB BATRK FWONB LSXMA FWONK P BATRB LSXMK BATRR BATRA FWONA
Does the world really need another streaming music service? Well, Alphabet Inc (NASDAQ:GOOGL)(NASDAQ:GOOG) thinks so. The company has recently launched its own platform called YouTube Music. It is initially available in the U.S., Mexico, Australia, New Zealand and South Korea.
FB AMZN SPOT GOOGL TWTR AAPL P GOOG
The music business has been a crowded space for a while, said Pandora CEO Roger Lynch. To compete, the media streaming company added yet another subscription service to its platform: the Pandora Premium Family plan.
CBS Corporation (NYSE:CBS) is an awkward position. CBS stock is held captive by the legal maneuvering of the heir to a still-living 95-year-old business magnate, Sumner Redstone. A flurry of lawsuits and bad blood has left CBS stockholders in a state of confusion.
CBS CBS.A VIAB P NFLX CPV CBS.WD
2017-11-09 - Asif
Pandora is the world’s most powerful music discovery platform, offering a personalized experience for each of its listeners wherever and whenever they want to listen to music—whether through earbuds, car speakers or home audio/video equipment. The company's vision is to be the definitive source of music discovery and enjoyment for billions of users. Pandora is available as an ad-supported service, a radio subscription service called Pandora Plus and an on-demand subscription service called Pandora Premium. The majority of its listener hours occur on mobile devices, with the majority of its revenue generated from advertising on its ad-supported service on these devices. The company offer both local and national advertisers the opportunity to deliver targeted messages to its listeners using a combination of audio, display and video advertisements. The company also generate revenue from subscriptions to Pandora Plus and Pandora Premium. Founded by musicians, Pandora also empowers artists ...
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to P / Pandora Media, Inc. on message board site Silicon Investor.
as of ET